Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800968 | 0.88 | F10 (0.46) | CALML3F10MAOAMAOB | |
| SCHEMBL2798683 | 0.84 | MAOA (0.51) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL2800501 | 0.83 | F10 (0.54) | F10 | |
| SCHEMBL13232200 | 0.79 | F10 (0.69) | F10 | |
| SCHEMBL20511388 | 0.78 | CALML3 (0.55) | CALML3F10MAOAMAOBCYP3A4 | |
| SCHEMBL20511389 | 0.78 | CALML3 (0.55) | CALML3F10MAOAMAOBCYP3A4 | |
| SCHEMBL2796423 | 0.77 | F10 (0.56) | F10 | |
| SCHEMBL18786445 | 0.77 | CALML3 (0.60) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL18786417 | 0.77 | CALML3 (0.60) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL3523994 | 0.77 | F10 (0.59) | CALML3F10MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, TFPI | CALML3 4102/4885F10 4/4885MAOA 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.